Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

With the development of molecular cloning technology and the deep understanding of
antibody engineering, there are diverse bispecific antibody formats from which to choose to …

Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of
the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled …

Shedding of membrane-bound cell surface proteins, where the extracellular domain is
released and found in the circulation is a common phenomenon. A prominent example is …

Cancer immunotherapy has recently generated much excitement after the continuing
success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various …

Reducing the dimension of antigen-binding proteins to an only immunoglobulin domain has
been one of the objectives of antibody manufacturing. Heavy chain antibodies were …

Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin
conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 …

ABSTRACT CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC)
and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody …